Clinical trials have traditionally measured patient outcomes through periodic clinic visits — a blood pressure reading, a questionnaire, a physical exam, captured at scheduled intervals weeks or months apart. Digital biomarkers offer a fundamentally different approach: continuous, objective measurement of a patient’s health status using wearable devices and sensors, generating far richer data than intermittent clinic visits can capture. For biotech investors, digital biomarker technology is increasingly relevant both as a standalone commercial opportunity and as a tool reshaping how clinical trials themselves are designed and conducted.
The Short Answer
| A digital biomarker is a characteristic or set of characteristics, collected from digital health technologies such as wearable sensors, smartphones, or other connected devices, that is used as an indicator of normal biological processes, disease processes, or response to an intervention. Unlike traditional biomarkers measured through a blood test or imaging scan at a discrete point in time, digital biomarkers are typically collected continuously or at high frequency in the patient’s everyday environment, generating longitudinal data that can reveal patterns invisible to periodic clinic-based assessment. |
How Consumer Technology Became a Clinical Research Tool
The emergence of digital biomarkers as a serious clinical research category tracks closely with the proliferation of consumer wearable devices — fitness trackers and smartwatches from the mid-2010s onward, which normalized continuous personal health data collection at a population scale never previously possible. What began as consumer wellness technology increasingly demonstrated its potential as a source of clinically meaningful data.
The FDA formally began addressing digital health technologies in clinical trials with a series of guidance documents starting in the late 2010s, culminating in more comprehensive guidance on digital health technologies for remote data acquisition in clinical investigations. The COVID-19 pandemic significantly accelerated adoption of decentralized clinical trial elements, including digital biomarker collection, as in-person clinic visits became difficult or impossible during periods of restricted movement — demonstrating both the feasibility and the value of continuous remote monitoring at scale.
Types of Digital Biomarkers in Clinical Use
Actigraphy — measuring movement and activity patterns through accelerometer data — is one of the most established digital biomarker categories, used to assess sleep quality, physical activity levels, and functional status in conditions ranging from depression to Parkinson’s disease to oncology-related fatigue. Continuous glucose monitors, now widely used clinically for diabetes management, generate rich digital biomarker data that has also found application in broader metabolic and cardiovascular research.
Voice and speech analysis is an emerging digital biomarker category, particularly relevant to neurological and psychiatric conditions — changes in speech patterns, cadence, and vocabulary have shown correlation with cognitive decline in Alzheimer’s disease and other neurodegenerative conditions, and with mood states in psychiatric conditions. Passive smartphone data — typing patterns, app usage, geolocation patterns reflecting social engagement — is being studied as a digital biomarker for depression and other psychiatric conditions, though this category raises significant privacy considerations that companies and regulators are actively navigating.
Digital Endpoints in Clinical Trials — A Regulatory Evolution
The most significant development for biotech investors is the FDA’s growing acceptance of digital biomarkers as formal clinical trial endpoints — not just supplementary data, but the actual pre-specified measure used to determine whether a drug meets its primary efficacy endpoint. A digital endpoint derived from continuous wearable data can, in some cases, detect a treatment effect more sensitively than a traditional clinic-based assessment, because it captures the patient’s actual functional status in their real environment rather than a single, potentially unrepresentative clinic visit.
Regulatory acceptance of digital endpoints requires rigorous validation — demonstrating that the specific digital measure genuinely reflects the clinically meaningful outcome the trial intends to assess, and that the measurement methodology is reliable and reproducible across the patient population and device types being used. This validation process itself has become an area of active collaboration between the FDA, academic researchers, and industry consortiums.
Decentralized Clinical Trials and the Broader Trend
Digital biomarkers are a core enabling technology for decentralized clinical trials — trials designed to reduce or eliminate the need for patients to travel to a central clinical site for every assessment, instead conducting much of the trial remotely through digital tools, local labs, and home health visits. Decentralized approaches can improve patient recruitment and retention, particularly for patients who live far from major medical centers or have mobility limitations, and can reduce the operational cost and complexity of running large trials. Companies building digital biomarker and decentralized trial infrastructure — as well as pharmaceutical companies incorporating these tools into their trial designs — represent a growing intersection of healthcare technology and traditional biotech investing.
What This Does Not Guarantee
| The use of digital biomarkers in a clinical trial does not guarantee that the trial will succeed, nor does it guarantee that the FDA will accept a novel digital endpoint without extensive validation. Digital biomarker technology faces real technical challenges, including device and algorithm variability, differences in patient adherence to wearing devices consistently, and the ongoing need to establish that a given digital measure genuinely correlates with meaningful clinical benefit rather than simply being an easily-collected proxy. Investors should evaluate digital biomarker strategies with the same clinical rigor applied to any other trial design element. |
Key Takeaways
- Digital biomarkers use wearable devices and connected technology to continuously measure health data outside the clinical setting, generating richer longitudinal data than periodic clinic visits
- Established categories include actigraphy (movement/sleep), continuous glucose monitoring, and emerging voice/speech and smartphone-based digital biomarkers
- The FDA has issued growing guidance on digital health technologies for clinical trials, including their use as formal digital endpoints in select cases
- A validated digital endpoint can sometimes detect a treatment effect more sensitively than a traditional clinic-based assessment by capturing real-world functional status
- Digital biomarkers are a core enabling technology for decentralized clinical trials, which reduce the need for patients to travel to central sites
- COVID-19 significantly accelerated adoption of remote and digital trial elements across the industry
- Digital biomarker use does not guarantee trial success or automatic regulatory acceptance — rigorous validation of the specific measure remains required
Sources
1. FDA — Digital Health Technologies for Remote Data Acquisition: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations
2. FDA — Digital Health Center of Excellence: https://www.fda.gov/medical-devices/digital-health-center-excellence
3. NIH — Digital Biomarkers: https://ncats.nih.gov
4. ClinicalTrials.gov: https://clinicaltrials.gov
Disclaimer
This article is based on publicly available regulatory information, company filings, and authoritative industry sources. All information was current as of the date of publication. BioTech Stocks Daily has not received compensation from any company referenced in this article in connection with this coverage.
This article contains references to forward-looking statements and clinical projections. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those projected. Past clinical results do not guarantee future outcomes.
The information provided in this article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decision.
For full terms, see our Disclaimer.
